Received Jun 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | IM |
Received Heplisav-B first dose received on 1/29/2025, then patient received Engerix on 2/17/2025, and then received Heplisav-B on 2/26/2025.; Received Heplisav-B first dose received on 1/29/2025, then patient received Engerix on 2/17/2025, and then received Heplisav-B on 2/26/2025.; Initial report received on 27-May-2025. A medical assistant reported that a male patient received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization, then received ENGERIX-B, and then received the second dose of HEPLISAV-B four weeks after the first. No medical history or concomitant medications were reported. On 29-Jan-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #,expiration date, NDC #, route, and site not available)]. On 17-Feb-2025, 19 days after receiving dose 1 of HEPLISAV-B, the patient received a dose of a hepatitis b vaccine [ENGERIX-B (lot #, expiration date, NDC #, route, and site not available)]. On 26-Feb-2025, 28 days after receiving dose 1 of HEPLISAV-B, the patient received dose 2 of a HEPLISAV-B (lot #, expiration date, NDC #). No adverse reactions were reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.